Physician

Nouman Asif, M.D.

According to 2025 Medicare claims, Nouman Asif, M.D. (NPI: 1790947174) practices medical oncology in the Frederick-Gaithersburg-Bethesda, MD market, with the plurality of this provider's patient population coming from Frederick, MD. This provider's primary affiliated billing organization is MARYLAND ONCOLOGY HEMATOLOGY P.A. (NPI: 1396710703; TIN: 113652573) and primary practice location at 21702-4501. Asif is affiliated with the ACO West Virginia (ACO ID: A3563), participating under the MSSP model.

Asif's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 967 traditional Medicare patients, billed 274,267 HCPCS/CPT codes, and received $5,468,882 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,087 prescription claims across 195 beneficiaries totaling $2,806,210 in drug costs, led by Brukinsa (Zanubrutinib). DME data shows 47 claims. Open Payments data shows 44 records totaling $1,242. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $225,523 to $5,468,882. Similarly, Part D prescription costs have risen steadily, from $620,328 to $2,806,210. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	564	25,026	$225,523
2016	229	42,097	$496,802
2017	331	148,829	$1,041,399
2018	543	188,847	$1,207,687
2019	573	179,531	$1,629,350
2020	530	129,675	$1,617,675
2021	812	271,110	$3,054,446
2022	965	450,011	$4,268,371
2023	927	306,929	$5,331,417
2024	967	274,267	$5,468,882

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	167	620	$620,328
2016	75	232	$274,750
2017	102	757	$1,284,443
2018	84	572	$1,079,184
2019	97	590	$1,275,223
2020	94	563	$1,110,826
2021	129	645	$862,536
2022	185	1,128	$2,601,572
2023	196	993	$2,469,209
2024	195	1,087	$2,806,210

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	94	$8,250
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	12	$1,505
2022	N/R	11	$960
2023	N/R	29	$4,637
2024	N/R	47	$1,445

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	378	741	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	567	954	$66
82728	Ferritin (blood protein) level	286	752	$13
80053	Blood test, comprehensive group of blood chemicals	417	1,489	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	561	2,707	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	22	660	$343,272
Nerlynx	Neratinib Maleate	16	479	$338,146
Xtandi	Enzalutamide	23	690	$325,217
Calquence	Acalabrutinib Maleate	21	630	$324,450
Tasigna	Nilotinib Hcl	13	364	$241,568

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	22	$974
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	25	$471

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	44	$1,242	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Nouman Asif, M.D.?

Tedicare shows public-source Medicare data for Nouman Asif, M.D. (NPI 1790947174), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Nouman Asif, M.D. have ACO affiliation data?

Nouman Asif, M.D. is shown with ACO affiliation data for ACO West Virginia (MSSP, ACO ID A3563).

What billing organization is linked to Nouman Asif, M.D.?

Nouman Asif, M.D. is linked to MARYLAND ONCOLOGY HEMATOLOGY P.A. (billing NPI 1396710703) in the available physician profile data.

Does Nouman Asif, M.D. have Open Payments data?

Nouman Asif, M.D. has 44 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.